Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice
- PMID: 22884069
Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice
Abstract
Background: Immunosuppressive regulatory T cells (Tregs) participate in tumor immune evasion and the number and suppressive function of Tregs change with the aging process, but it is not clear whether such change leads to a higher incidence of tumors in the elderly. To this end, we designed experiments to explore the changes of Tregs and the functional gene Forkhead box P3 (FoxP3) in the aging process and its relationship with lung tumors in humans and mice.
Methods: The percentage of CD4(+)CD25(+)CD127(low) Tregs and expression of FoxP3 mRNA were analyzed using flow cytometry (FCM) and real-time fluorescence-based quantitative polymerase chain reaction (FQ-PCR). Markers were analyzed in the peripheral blood (PB) of 65 elderly patients (age ≥ 65 years) with primary non-small cell lung cancer (NSCLC), 20 younger patients (aged < 55 years) with NSCLC, 30 elderly healthy individuals and 30 young healthy individuals. Furthermore, we set up the Lewis lung cancer model with C57BL/6 female mice. Thirty-six mice were divided into a young healthy group, a middle-aged healthy group, an elderly healthy group, a young tumor group, a middle-aged tumor group, and an elderly tumor group. The percentage of CD4(+)CD25(+)FoxP3(+) Tregs and the expression level of FoxP3 mRNA in splenocytes were determined in the six groups.
Results: The percentage of peripheral CD4(+)CD25(+)CD127(low) Tregs and the expression of FoxP3 mRNA were significantly increased in elderly patients with NSCLC comparing with the other groups and in elderly healthy individuals compared with young healthy individuals. Further analysis showed that the percentage of CD4(+)CD25(+)CD127(low) Tregs and the expression of FoxP3 mRNA were closely associated with tumor node metastasis (TNM) staging in elderly patients with NSCLC. In the mouse model, the percentage of CD4(+)CD25(+)FoxP3(+) Tregs and the expression of FoxP3 mRNA in splenocytes of the tumor groups were significantly higher than in the healthy groups, with the highest expression in the elderly tumor group. In the healthy groups, the elderly healthy mice had the highest percentage of Tregs and expression of FoxP3 mRNA. The elderly mice had larger and heavier tumors than did the young and middle aged mice.
Conclusions: The up-regulation of Tregs and the FoxP3 gene with aging may play an essential role in oncogenesis and development of lung tumors in an elderly population.
Similar articles
-
No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.Diabetes. 2007 Mar;56(3):604-12. doi: 10.2337/db06-1248. Diabetes. 2007. PMID: 17327427
-
Suppression of alloimmunity in mice by regulatory T cells converted with conditioned media.J Surg Res. 2011 Dec;171(2):797-806. doi: 10.1016/j.jss.2010.03.044. Epub 2010 Apr 15. J Surg Res. 2011. PMID: 20538297
-
CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.Chin Med J (Engl). 2010 Apr 5;123(7):942-8. Chin Med J (Engl). 2010. PMID: 20497692
-
[CD4+CD25+Foxp3+ T lymphocytes: naturally occuring regulatory T cells].Pediatr Endocrinol Diabetes Metab. 2010;16(4):289-94. Pediatr Endocrinol Diabetes Metab. 2010. PMID: 21447271 Review. Polish.
-
CD4+CD25+ regulatory T cells in tumor immunity.Int Immunopharmacol. 2016 May;34:244-249. doi: 10.1016/j.intimp.2016.03.009. Epub 2016 Mar 16. Int Immunopharmacol. 2016. PMID: 26994448 Review.
Cited by
-
Age-related autoimmunity.BMC Med. 2013 Apr 4;11:94. doi: 10.1186/1741-7015-11-94. BMC Med. 2013. PMID: 23556986 Free PMC article.
-
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.Transl Lung Cancer Res. 2019 Aug;8(4):450-460. doi: 10.21037/tlcr.2019.08.07. Transl Lung Cancer Res. 2019. PMID: 31555518 Free PMC article.
-
Optimization of immunotherapy in elderly cancer patients.Crit Rev Oncog. 2013;18(6):573-83. doi: 10.1615/critrevoncog.2013010591. Crit Rev Oncog. 2013. PMID: 24579736 Free PMC article. Review.
-
Immunosenescence: a key player in cancer development.J Hematol Oncol. 2020 Nov 10;13(1):151. doi: 10.1186/s13045-020-00986-z. J Hematol Oncol. 2020. PMID: 33168037 Free PMC article. Review.
-
Age matters: Young T lymphocytes offer better protection from myeloma proliferation.Immun Ageing. 2013 Feb 18;10(1):5. doi: 10.1186/1742-4933-10-5. Immun Ageing. 2013. PMID: 23419047 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials